Alteration of dopamine D2 receptors in human malignant stomach tissue.
Dopamine is an important enteric neurotransmitter with a wide spectrum of physiological actions on the gastrointestinal tract. In addition, it showed inhibition of malignant cell proliferation as well as a protective influence on experimental carcinogenesis in the gastrointestinal tract of murine hosts. It is well established that dopamine acts on target cells through specific receptors. Therefore the status of dopamine receptors in malignant tumors of the stomach has been evaluated. Normal, benign, and malignant stomach tissue showed the presence of high-affinity D2 dopamine receptors. The concentration (Bmax) and affinity (Kd) of dopamine binding sites in normal and benign tumor tissues were similar. In malignant stomach tissue Bmax showed a significant decrease compared to normal and benign controls; however, Kd was similar. This alteration of dopamine receptors may be of significance in understanding the etiopathogenesis of gastric cancer at the level of peripheral neurotransmitters. Rational use of dopamine receptor antagonists for various stomach diseases may be suggested.
Basu
S
S
Department of Medical Oncology, Chittaranjan National Cancer Institute, Calcutta, India.
Dasgupta
P S
PS
D000230:Adenocarcinoma / Q000378:metabolism*; D001665:Binding Sites; D004298:Dopamine / Q000378:metabolism*; D005753:Gastric Mucosa / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017448:Receptors, Dopamine D2 / Q000378:metabolism*; D013270:Stomach / Q000473:pathology; D013274:Stomach Neoplasms / Q000378:metabolism*; D014316:Tritium
D017448:Receptors, Dopamine D2; D014316:Tritium; D004298:Dopamine